

Data Sheet

 Product Name:
 Mertansine

 Cat. No.:
 CS-5804

 CAS No.:
 139504-50-0

 Molecular Formula:
 C35H48CIN3O10S


Molecular Weight: 738.29

Target: ADC Cytotoxin; Microtubule/Tubulin

Pathway: Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA

Damage; Cytoskeleton

Solubility: DMSO: 62.5 mg/mL (ultrasonic)



BIOLOGICAL ACTIVITY:

Mertansine (DM1) is a **microtubulin** inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC)^{[1][2]}. *In Vitro:* Mertansine is a strong antiproliferative chemotherapeutics toward over 60 types of cancer cell lines^[3].

Mertansine (0-1 μ g/mL) shows antitumor activity in malignant B16F10 melanoma cells, and inhibits tumor cell growth by inhibiting mitosis when combined with DTX^[3]. *In Vivo*: Mertansine (DM1) has a low maximum-tolerated dose (MTD) of 1 mg/kg^[3]

References:

- [1]. Manu Lopus et al. Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules.
- [2]. Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 2011 Aug 28;307(2):113-8.
- [3]. Zhong P, et al. cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. Nanotechnology. 2017 Jul 21;28(29):295103.

CAIndexNames:

Maytansine, N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-

SMILES:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr., Suite F., Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com